Roche launches next-generation qPCR system to advance clinical needs in molecular diagnostics
The new system raises the bar for performance and usability while bridging the gap between translational research and in vitro diagnostics.
Roche announced the launch of the LightCycler PRO System based on the proven gold standard technology of the LightCycler Systems that came before it. This new system raises the bar for performance and usability while bridging the gap between translational research and in vitro diagnostics. The LightCycler PRO System further complements Roche’s molecular PCR testing portfolio, which includes solutions for a variety of healthcare professionals – from those performing research to those testing patients for cancer, infectious diseases, and other public health challenges.
“Roche has made significant contributions in establishing and advancing PCR technology to address the needs of healthcare systems,” said Josh Lauer, Head of Molecular Labs, Roche Diagnostics. “We have listened to laboratories and hospitals and implemented their feedback, which has driven important design improvements. Healthcare systems have experienced significant resource constraints and rapidly shifting dynamics post-pandemic. The LightCycler PRO addresses those dynamics by offering the flexibility to switch seamlessly between research and clinical applications.”
The system will allow users to develop their tests and will also enable a portfolio of more than 200 LightMix Modular research assays and over 60 LightMix CE-IVD assays from the Roche subsidiary, TIB Molbiol.
The system will launch in select countries by the end of 2023, with plans to launch into more countries in future. It will be CE-marked and have an FDA 510(k) exempt status.
